Joint Formulary & PAD

Clascoterone - Acne

You are here : Home > Formulary Search > Clascoterone - Acne

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Cream
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NFD2
SPC
Restrictions / Comments :

This drug has not yet been assessed for formulary status.
NICE is unable to make a recommendation because the company has not provided an evidence submission. NICE therefore terminated its appraisal and as such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 
Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.
If a specialist team would like the APC to consider adding this treatment to the Joint Formulary. They should contact the team at syheartlandsicb.apc@nhs.net and the team will provide support for the submission.

NICE are due to publish guidance on this drug - date to be confirmed. This will be considered by the APC within 90 days of publication.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Clascoterone
Indication :
Acne
Group Name :
Keywords :
Acne vulgaris
Brand Names Include :
Winlevi
Important Information :

Acne vulgaris. Not assessed for inclusion on formulary. NICE publication date to be confirmed. 

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (0)

  • No records returned.

Other Indications

Below are listed other indications that Clascoterone is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Acne.